Afinitor and Gastrointestinal hypomotility - a phase IV clinical study of FDA data

Summary:

Gastrointestinal hypomotility is reported as a side effect among people who take Afinitor (everolimus), especially for people who are female, 50-59 old, also take Allegra, and have Fever.

The phase IV clinical study analyzes which people have Gastrointestinal hypomotility when taking Afinitor. It is created by eHealthMe based on reports of 41,609 people who have side effects when taking Afinitor from the FDA, and is updated regularly.

What is Afinitor?

Afinitor has active ingredients of everolimus. It is often used in breast cancer metastatic. eHealthMe is studying from 41,680 Afinitor users. Check the latest studies of Afinitor.

What is Gastrointestinal hypomotility?

Gastrointestinal hypomotility (less activity of the intestinal tract) is found to be associated with 204 drugs and 437 conditions by eHealthMe. Check the latest studies of Gastrointestinal hypomotility.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

41,609 people reported to have side effects when taking Afinitor.
Among them, 11 people (0.03%) have Gastrointestinal hypomotility.

Could Afinitor cause Gastrointestinal hypomotility?

Among these 11 people:

What is the gender of people who have Gastrointestinal hypomotility when taking Afinitor? *

female: 81.82 %
male: 18.18 %

What is the age of people who have Gastrointestinal hypomotility when taking Afinitor? *

What are other drugs people take besides Afinitor? *

What are other side effects people have besides Gastrointestinal hypomotility? *

Fever: 9 people, 81.82%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 9 people, 81.82%
Cardiac Function Test Abnormal: 9 people, 81.82%
Oropharyngeal Pain: 9 people, 81.82%
Cardiomyopathy (weakening of the heart muscle): 9 people, 81.82%
Malignant Neoplasm Progression (cancer tumour came back): 9 people, 81.82%
Chills (felling of cold): 9 people, 81.82%
Inflammation: 9 people, 81.82%
Headache (pain in head): 9 people, 81.82%
Cholangitis (infection of the bile duct): 9 people, 81.82%

What are the existing conditions these people have? *

Reflux Oesophagitis (an oesophageal mucosal injury that occurs of gastric contents into the oesophagus): 9 people, 81.82%
Rashes (redness): 9 people, 81.82%
Pancreatitis Chronic (chronic inflammation of pancreas): 9 people, 81.82%
Pancreatic Neuroendocrine Tumor: 9 people, 81.82%
Insomnia (sleeplessness): 9 people, 81.82%
Hypokalemia (low potassium): 9 people, 81.82%
Hepatic Function Abnormal: 9 people, 81.82%
Headache (pain in head): 9 people, 81.82%
Fungal Nail Infection: 9 people, 81.82%
Fever: 9 people, 81.82%

* Approximation only. Some reports may have incomplete information.

Do you take Afinitor and have Gastrointestinal hypomotility?

- Check whether Gastrointestinal hypomotility is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Afinitor:

Afinitor (41,680 reports)

Browse all side effects of Afinitor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gastrointestinal hypomotility:

Gastrointestinal hypomotility (204 drugs)

Browse all the conditions that are associated with Gastrointestinal hypomotility:

Gastrointestinal hypomotility (437 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on everolimus (the active ingredients of Afinitor) and Afinitor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.